Replies to post #273214 on Amarin Corp Plc (AMRN)

[Jason1689]

Hi jomama9231,

Pls help check another big error of Judge Du about Kurabayashi.
In the study, Kurabayashi reports a statistically significant 27% reduction in triglyceride levels in the EPA group.

Kurabayashi further reports that“[l]ow-density lipoprotein cholesterol levels in both groups were significantly lower”. So Estriol can reduce Low-density lipoprotein cholesterol(LDL-C) significantly, somewhat like Stain.

When administering EPA and Estriol, EPA reduces triglyceride(TG) and Estriol reduces LDL-C, They both will synergistic reduce the cardiovascular risk, the same as administering ERA and Stain in the study REDUCE-IT. They also will synergistic reduce Apo-B since Apo-B is a predictor of cardiovascular risk.

So maybe there is not any interaction or synergy in reducing TG and LDL-C, but with regard to Apo-B, there is absolutely a synergistic effect between EPA and Estriol. Judge Du said that “The results reported in Kurabayashi do not suggest any interaction or synergy between EPA and estriol” is clearly factual error. The conclusion that “a POSA would have attributed the reduction in Apo B to EPA.”(Id.at737:24-738:8) is completing wrong.

[Jason1689]

So to disentangle the effects of estriol from the effects of EPA, you have to do the between group comparison.

In the generics proposed findings of fact and conclusions of law at pages 246 and 247,
Heinecke said that "the study showed that estriol increased triglycerides, whereas EPA reduced them. Thus, the two compounds were antagonistic, nor synergistic. Heinecke Tr. 735:21-736:9."

He did not mention estriol decrease the LDL–C, I think this point is very important.

I donot know whether my understanding is right or not, pls help me check it, thank you.